The big question at the beginning of this year was whether investors would continue to eagerly buy up shares offered in new biotech IPOs, continuing the burst of new offerings that injected billions of dollars into the industry last year. As of today, the answer--for at least a few select biotechs--is a boisterous "yes."
Renaissance Capital counted three biotechs among the mix of IPOs expected to price this week. They run the gamut from Ultragenyx, a 2013 Fierce 15 winner with a pipeline of experimental therapies for rare diseases, to Cara Therapeutics and Dicerna.
Back in September, when Ultragenyx CEO Emil Kakkis was talking to FierceBiotech about the company for our annual Fierce 15 report, the biotech chief confidently predicted that he could take the company public next year.
Our annual Fierce 15 report on a top class of up-and-coming private biotechs came out today and I wanted to highlight the responses from many of the companies which are on the list. Read more | Check out this year's report
Last year when Ryan McBride and I were sorting through our short list of candidates, we both felt that Seaside Therapeutics deserved a spot on the list. The small company had raised a considerable...
Flush from raising more than $100 million, Novato, CA-based startup Ultragenyx Pharmaceutical has stepped up with a new pact to partner on a rare bone-disease drug from Japan's Kyowa Hakko Kirin.
Fresh from adding $75 million in venture cash to its accounts, Novato, CA-based Ultragenyx has picked another rare-disease drug candidate, plucking a program from the Baylor Research Institute in Dallas.
Little Novato, CA-based Ultragenyx has gone to a long lineup of backers to add a whopping $75 million in Series B cash only two years after launching.
Ultragenyx Pharmaceuticals has reloaded its coffers after the startup developer of rare disease drugs advanced its lead candidate for hereditary inclusion body myopathy into a Phase II study. According to an SEC filing, the Novato, CA-based biotech has raised a fresh $15.1 million.
An upstart biotech based in Novato, CA and focused on developing new drugs for rare diseases has hauled in an impressive $45 million A round from some high-profile venture backers. TPG Biotech and